ADMA News and Press, ADMA Biologics Inc From 02/08/23

ADMA Biologics ( NASDAQ: ADMA ) it had received U.S. Food and Drug Administration approval for its eighth ADMA BioCenters plasma collection facility located in Hammond. The facility is now licensed to collect, and introduce into interstate commerce, human source plasma for furthe...

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and HAMMOND, La., Feb. 08, 2023 (GLOBE NEWSWIRE) -- A...

ADMA Biologics ( NASDAQ: ADMA ), a biotech focused on plasma-derived treatments, added ~3% pre-market Tuesday after pre-announcing its Q4 2022 and full-year financials and setting its 2023 outlook ahead of Wall Street forecasts. Based on preliminary unaudited, the company expects ...

Fourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Revenues are...

Summary ADMA Biologics continues to outperform benchmarks, after offering investors a source of tactical alpha across the past 18 months. The market continues to reward its hypothesis in treating primary humoral immunodeficiency. Shares have extended the rally in 2023 and further up...

Adma Biologics ( NASDAQ: ADMA ) said the U.S. Food and Drug Administration (FDA) approved the room temperature (25°C) storage conditions of for its Asceniv and Bivigam immune globulin ( IG ) drug products for up to 4 weeks during the first 24 months of the 36-month approved s...

FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for improved inventory management and ease of product administration to patients Appro...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics...

ADMA Biologics ( NASDAQ: ADMA ) shares fell 4% premarket on Wednesday after the biopharmaceutical company priced its underwritten public offering of 20,979,020 shares of its common stock at $2.86 each. The underwriters have been granted a 30-day option to purchase up to 3,146,...

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics...